Warning! GuruFocus detected
5 Severe warning signs
with IPA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
ImmunoPrecise Antibodies Ltd
NAICS : 325412
SIC : 3741
ISIN : CA45257F1018
Description
ImmunoPrecise Antibodies Ltd is a biotherapeutic research and technology firm. It is distinguished by its proficiency in both in silico and wet lab methodologies. The company leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.99 | |||||
| Beneish M-Score | -3.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7 | |||||
| 3-Year EBITDA Growth Rate | -111.7 | |||||
| 3-Year EPS without NRI Growth Rate | -5.6 | |||||
| 3-Year FCF Growth Rate | -18 | |||||
| 3-Year Book Growth Rate | -27.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.36 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.54 | |||||
| 9-Day RSI | 64.96 | |||||
| 14-Day RSI | 59.08 | |||||
| 3-1 Month Momentum % | -16.33 | |||||
| 6-1 Month Momentum % | -33.25 | |||||
| 12-1 Month Momentum % | -71.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.32 | |||||
| Quick Ratio | 2.11 | |||||
| Cash Ratio | 1.45 | |||||
| Days Inventory | 65.26 | |||||
| Days Sales Outstanding | 52.19 | |||||
| Days Payable | 147.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12 | |||||
| Shareholder Yield % | -58.63 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.78 | |||||
| Operating Margin % | -60.89 | |||||
| Net Margin % | -193.09 | |||||
| FCF Margin % | -39.74 | |||||
| ROE % | -131.34 | |||||
| ROA % | -75.54 | |||||
| ROIC % | -25.68 | |||||
| 3-Year ROIIC % | -26.62 | |||||
| ROC (Joel Greenblatt) % | -296.75 | |||||
| ROCE % | -98.2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.75 | |||||
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.83 | |||||
| EV-to-EBIT | -0.54 | |||||
| EV-to-EBITDA | -0.61 | |||||
| EV-to-Revenue | 1.14 | |||||
| EV-to-Forward-Revenue | 0.95 | |||||
| EV-to-FCF | -2.87 | |||||
| Price-to-GF-Value | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 45.71 | |||||
| Earnings Yield (Greenblatt) % | -185.19 | |||||
| FCF Yield % | -32.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IPA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
ImmunoPrecise Antibodies Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17.289 | ||
| EPS (TTM) ($) | -1.16 | ||
| Beta | -0.01 | ||
| 3-Year Sharpe Ratio | -1.17 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 47.94 | ||
| 14-Day RSI | 59.08 | ||
| 14-Day ATR ($) | 0.053647 | ||
| 20-Day SMA ($) | 0.40644 | ||
| 12-1 Month Momentum % | -71.7 | ||
| 52-Week Range ($) | 0.27 - 1.39 | ||
| Shares Outstanding (Mil) | 45.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmunoPrecise Antibodies Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmunoPrecise Antibodies Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmunoPrecise Antibodies Ltd Frequently Asked Questions
What is ImmunoPrecise Antibodies Ltd(IPA)'s stock price today?
The current price of IPA is $0.46. The 52 week high of IPA is $1.39 and 52 week low is $0.27.
When is next earnings date of ImmunoPrecise Antibodies Ltd(IPA)?
The next earnings date of ImmunoPrecise Antibodies Ltd(IPA) is 2025-07-29 Est..
Does ImmunoPrecise Antibodies Ltd(IPA) pay dividends? If so, how much?
ImmunoPrecise Antibodies Ltd(IPA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers